Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2014 Apr;95(4):376-82.
doi: 10.1038/clpt.2013.254. Epub 2014 Jan 23.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update

K R Crews  1 , A Gaedigk  2 , H M Dunnenberger  1 , J S Leeder  2 , T E Klein  3 , K E Caudle  1 , C E Haidar  1 , D D Shen  4 , J T Callaghan  5 , S Sadhasivam  6 , C A Prows  7 , E D Kharasch  8 , T C Skaar  9 ; Clinical Pharmacogenetics Implementation Consortium
Affiliations
Practice Guideline

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update

K R Crews et al. Clin Pharmacol Ther. 2014 Apr.

Abstract

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Codeine metabolism pathway in an individual with cytochrome P450 2D6 (CYP2D6) extensive metabolism. Asterisks (*) denote active metabolites.
See this image and copyright information in PMC

References

    1. Crews K.R., et al. Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 2012;91:321–326. - PMC - PubMed
    1. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjöqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA. 1993;90:11825–11829. - PMC - PubMed
    1. Gaedigk A., Simon S.D., Pearce R.E., Bradford L.D., Kennedy M.J., Leeder J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 2008;83:234–242. - PubMed
    1. Borges S., et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J. Clin. Pharmacol. 2010;50:450–458. - PMC - PubMed
    1. Gaedigk A., Gotschall R.R., Forbes N.S., Simon S.D., Kearns G.L., Leeder J.S. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999;9:669–682. - PubMed

Publication types

MeSH terms